Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer

Authors: Aimee A. D’Aloisio, Hazel B. Nichols, M. Elizabeth Hodgson, Sandra L. Deming-Halverson, Dale P. Sandler

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Women may have incomplete understanding of a breast cancer diagnosis, leading to inaccurate reporting in epidemiological studies. However, it is not feasible to obtain consent for medical records from all women participating in a study. Therefore, it is important to determine how well self-reported breast cancer characteristics correspond with what is found in medical records, but few studies have evaluated agreement of self-reported breast cancer characteristics with abstracted medical records.

Methods

We calculated the positive predictive value (PPV) of self-reports compared to medical records and explored whether participant characteristics may have influenced reporting accuracy. We analyzed data from 2518 reported breast cancer cases from the Sister Study, a large nationwide cohort of women with a family history of breast cancer.

Results

Medical records or pathology reports were obtained for 2066 of 2518 (82%) women who reported incident breast cancer. Breast cancer was confirmed for over 99% (n = 2054) of women with medical records. Confirmation rates were high for invasive, ductal, hormone receptor positive, and HER2 negative breast cancers, with little variation by race/ethnicity or age. Self-reported in situ breast cancer had a lower PPV (64.2%), with medical records showing invasive breast cancer instead, especially for older and Hispanic women. Hormone receptor (ER and PR) negative and HER2 positive self-reports had lower PPVs (83.0%, 71.6%, and 66.1% respectively). Hispanic women and women ages 65 or older at diagnosis were less able to accurately report breast cancer stage, excluding stage I.

Conclusions

Accuracy of reporting overall breast cancer and common subtypes is high. Despite having a family history of breast cancer and voluntarily enrolling in a study evaluating breast cancer risk factors, participants may have greater difficulty distinguishing between in situ and invasive breast cancer and may less accurately report other less common subtypes. Discrepancies may reflect women’s poor understanding of information conveyed by health care providers or lack of consistent terminology used to describe subtypes.
Literature
1.
go back to reference Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL. Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J Clin Oncol. 2005;23(21):4679–86.CrossRefPubMed Phillips KA, Milne RL, Buys S, Friedlander ML, Ward JH, McCredie MR, Giles GG, Hopper JL. Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J Clin Oncol. 2005;23(21):4679–86.CrossRefPubMed
2.
go back to reference Maunsell E, Drolet M, Ouhoummane N, Robert J. Breast cancer survivors accurately reported key treatment and prognostic characteristics. J Clin Epidemiol. 2005;58(4):364–9.CrossRefPubMed Maunsell E, Drolet M, Ouhoummane N, Robert J. Breast cancer survivors accurately reported key treatment and prognostic characteristics. J Clin Epidemiol. 2005;58(4):364–9.CrossRefPubMed
3.
go back to reference Liu Y, Diamant AL, Thind A, Maly RC. Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer. Breast Cancer Res Treat. 2010;119(3):745–51.CrossRefPubMed Liu Y, Diamant AL, Thind A, Maly RC. Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer. Breast Cancer Res Treat. 2010;119(3):745–51.CrossRefPubMed
4.
go back to reference Bell RJ, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Davis SR. Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. J Women's Health (Larchmt). 2009;18(12):1975–80.CrossRef Bell RJ, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Davis SR. Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. J Women's Health (Larchmt). 2009;18(12):1975–80.CrossRef
5.
go back to reference Loh V, Harding J, Koshkina V, Barr E, Shaw J, Magliano D. The validity of self-reported cancer in an Australian population study. Aust N Z J Public Health. 2014;38(1) 35–8 Loh V, Harding J, Koshkina V, Barr E, Shaw J, Magliano D. The validity of self-reported cancer in an Australian population study. Aust N Z J Public Health. 2014;38(1) 35–8
6.
go back to reference Parikh-Patel A, Allen M, Wright WE. Validation of self-reported cancers in the California teachers study. Am J Epidemiol. 2003;157(6):539–45.CrossRefPubMed Parikh-Patel A, Allen M, Wright WE. Validation of self-reported cancers in the California teachers study. Am J Epidemiol. 2003;157(6):539–45.CrossRefPubMed
7.
go back to reference McCarthy AM, McGuire E, Bristol M, Fredricks T, Domchek SM, Armstrong K. Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. Cancer Epidemiol. 2013;37(5):601–5.CrossRefPubMedPubMedCentral McCarthy AM, McGuire E, Bristol M, Fredricks T, Domchek SM, Armstrong K. Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. Cancer Epidemiol. 2013;37(5):601–5.CrossRefPubMedPubMedCentral
8.
go back to reference Stavrou E, Vajdic CM, Loxton D, Pearson SA. The validity of self-reported cancer diagnoses and factors associated with accurate reporting in a cohort of older Australian women. Cancer Epidemiol. 2011;35(6):e75–80.CrossRefPubMed Stavrou E, Vajdic CM, Loxton D, Pearson SA. The validity of self-reported cancer diagnoses and factors associated with accurate reporting in a cohort of older Australian women. Cancer Epidemiol. 2011;35(6):e75–80.CrossRefPubMed
9.
go back to reference Schootman M, Jeffe DB, West MM, Aft R. Self-report by elderly breast cancer patients was an acceptable alternative to surveillance, epidemiology, and end results (SEER) abstract data. J Clin Epidemiol. 2005;58(12):1316–9.CrossRefPubMed Schootman M, Jeffe DB, West MM, Aft R. Self-report by elderly breast cancer patients was an acceptable alternative to surveillance, epidemiology, and end results (SEER) abstract data. J Clin Epidemiol. 2005;58(12):1316–9.CrossRefPubMed
10.
go back to reference Barisic A, Glendon G, Weerasooriya N, Andrulis IL, Knight JA. Accuracy of self-reported breast cancer information among women from the Ontario site of the breast cancer family registry. J Cancer Epidemiol. 2012;2012:310804.CrossRefPubMedPubMedCentral Barisic A, Glendon G, Weerasooriya N, Andrulis IL, Knight JA. Accuracy of self-reported breast cancer information among women from the Ontario site of the breast cancer family registry. J Cancer Epidemiol. 2012;2012:310804.CrossRefPubMedPubMedCentral
11.
go back to reference Freedman RA, Kouri EM, West DW, Keating NL. Racial/ethnic disparities in knowledge about one's breast cancer characteristics. Cancer. 2015;121(5):724–32.CrossRefPubMedPubMedCentral Freedman RA, Kouri EM, West DW, Keating NL. Racial/ethnic disparities in knowledge about one's breast cancer characteristics. Cancer. 2015;121(5):724–32.CrossRefPubMedPubMedCentral
13.
go back to reference Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentral Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentral
14.
go back to reference Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007;25(13):1683–90.CrossRefPubMed Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007;25(13):1683–90.CrossRefPubMed
15.
go back to reference Chen L, Linden HM, Anderson BO, Li CI. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat. 2014;147(3):609–16.CrossRefPubMedPubMedCentral Chen L, Linden HM, Anderson BO, Li CI. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat. 2014;147(3):609–16.CrossRefPubMedPubMedCentral
16.
17.
go back to reference Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, et al. Current challenges in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2016;98:211–21.CrossRefPubMed Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, et al. Current challenges in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2016;98:211–21.CrossRefPubMed
Metadata
Title
Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer
Authors
Aimee A. D’Aloisio
Hazel B. Nichols
M. Elizabeth Hodgson
Sandra L. Deming-Halverson
Dale P. Sandler
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3686-6

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine